Named on 5 rounds in the feed, most often in Biotech.
Rounds from 2020-11-18 to 2026-04-08
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Sidewinder Therapeutics Sidewinder Therapeutics specializes in developing bispecific antibody-drug conjugates aimed at treating difficult cancers for patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $137M | 2026-04-08 | [ PART ] |
Nilo Nilo Therapeutics develops medicines that target neural circuits to restore immune balance in autoimmune and inflammatory disease. | Series A Verified against 1 of 4 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $101M | 2025-10-08 | [ LEAD ] |
Umoja Biopharma Umoja Biopharma, a clinical-stage leader developing in vivo CAR T cell therapies. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-01-14 | [ LEAD ] |
Umoja Biopharma Umoja Biopharma, a clinical-stage leader developing in vivo CAR T cell therapies. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $210M | 2021-06-15 | [ PART ] |
Umoja Biopharma Umoja Biopharma, a clinical-stage leader developing in vivo CAR T cell therapies. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $53M | 2020-11-18 | [ PART ] |